Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:30:20 2024-05-13 am EDT			5-day change	1st Jan Change
43.1 ^CHF	+0.35%		+7.21%	+22.10%

May. 03	Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024	CI
Apr. 09	Basilea Pharmaceutica Receives Grant for Antibiotics Program	MT

Basilea Pharmaceutica AG Provides Earnings Guidance for the Full Year of Fiscal 2021

February 16, 2021 at 01:15 am EST

Basilea Pharmaceutica AG provided earnings guidance for the full year of fiscal 2021. For the full year, the company expects total revenue between CHF 128 million and CHF 138 million and operating loss between CHF 13 million and CHF 23 million.

Latest news about Basilea Pharmaceutica AG

Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024	May. 03	CI
Basilea Pharmaceutica Receives Grant for Antibiotics Program	Apr. 09	MT
Stocks Close in Green as Swiss Inflation Unexpectedly Slows	Apr. 04	MT
European stocks rise ahead of inflation data; Basilea shines	Apr. 04	RE
Basilea announces US FDA approval of antibiotic ZEVTERA(R) (ceftobiprole medocaril) for three indications	Apr. 04	DJ
US FDA Greenlights Basilea Pharmaceutical's Treatment for Bloodstream Infections	Apr. 04	MT
US FDA approves Basilea Pharmaceutica's antibiotic	Apr. 03	RE
US FDA approves Basilea Pharmaceutica's antibiotic	Apr. 03	RE
Basilea Pharmaceutica to Receive Milestone Payment from Pfizer for Antifungal Drug	Mar. 11	MT
Continued strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	Mar. 11	DJ
Stronger-than-Expected US Inflation Rate Weighs on Swiss Equities	Feb. 13	MT
Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2024	Feb. 13	CI
Transcript : Basilea Pharmaceutica AG, 2023 Earnings Call, Feb 13, 2024	Feb. 13
Basilea Pharmaceutica AG Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
Basilea Pharmaceutica Posts Lower FY23 Net Profit; Revenue Up	Feb. 13	MT
Spexis Completes CHF2 Million Sale of Antibiotics Program to Basilea	Feb. 08	MT
Basilea Pharmaceutica to Receive First Milestone Payment for Cresemba from Latin America	Jan. 19	MT
Basilea Pharmaceutica to Buy Preclinical Antibiotics Program Targeting Gram-negative Bacteria from Spexis	Jan. 15	MT
Global markets live: Walt Disney, Qiagen, Mobileye, Apple, CVS Health...	Jan. 05
Basilea Pharmaceutica Eyes Commercialization Partner for Ceftobiprole Ahead of US FDA Verdict	Jan. 05	MT
Global markets live: Fedex, Curevac, Shell, Fedex, Alphabet...	Dec. 20
Basilea Pharmaceutica Plans Early Repayment of Loan from Athyrium Capital	Dec. 20	MT
Basilea Pharmaceutica Ltd Announces Accelerated Loan Repayment	Dec. 20	CI
Basilea Pharmaceutica License Partner Obtains US FDA Approval for Expanded Use of Antifungal Medication	Dec. 11	MT
Swiss Equities Little Changed Amid Economic Data Spotlight, Julius Bär’s Profit Woes	Nov. 20	MT

Chart Basilea Pharmaceutica AG

Duration

Period

More charts

Company Profile

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Basilea Pharmaceutica AG

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

42.95 CHF

Average target price

70.58 CHF

Spread / Average Target

+64.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BASILEA PHARMACEUTICA AG	+22.10%	572M
MODERNA, INC.	+23.40%	44.96B
IQVIA HOLDINGS INC.	+0.51%	42.65B
LONZA GROUP AG	+46.00%	41.85B
CELLTRION, INC.	-5.31%	29.04B
ICON PUBLIC LIMITED COMPANY	+10.85%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.22%	19.03B
BIO-TECHNE CORPORATION	+6.25%	12.75B
MEDPACE HOLDINGS, INC.	+29.11%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.55%	11.75B

Other Biotechnology & Medical Research